united therapeutics glp-1 receptor agonist Frontiers Is biased agonism helpful in
Description
Following this strategy, different metabolic pathways for carbohydrate, lipid, and protein metabolism could be influenced simultaneously
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Stopping the medication often leads to weight regain for patients if permanent lifestyle changes were not made
Before, during, and after switching treatments, patient communication and reinforcement of educational messages are vital to ensure a smooth transition
10.1002/smll.202408581 Small 46 QianZ.ChenH.XiaM.ChangJ.LiX.YeS.et al (2022)
